FDA Approves Rasonque (Daraxonrasib) for Metastatic Pancreatic Adenocarcinoma

The Food and Drug Administration approved Rasonque (daraxonrasib) on August 26 for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy; this once-daily tablet is the first FDA-approved RAS inhibitor for this disease, targeting multiple RAS proteins that drive tumor growth. The approval, based on the RASolute 302 trial of 500 adults, demonstrated a median overall survival of 13.2 months for daraxonrasib versus 6.7 months for standard chemotherapy (hazard ratio 0.40, p<0.0001), along with median progression-free survival of 7.2 months vs. 3.6 months and objective response rates of 30% vs. 11%. Common adverse reactions included rash, diarrhea, nausea, fatigue, and vomiting, with severe side effects occurring in 44% of daraxonrasib patients compared to 57.5% with chemotherapy. Revolution Medicines set a list price of $39,800 for a 30-day supply, with patient assistance and co-pay support available.

The Price Tag That Tells the Real Story

Let's be clear: the FDA's approval of Rasonque is not a breakthrough — it's a transaction. And the numbers tell you everything the press release leaves out. Look at that list price: $39,800 for a 30-day supply. Do the math. That's nearly half a million dollars a year for a drug that extends median survival from six months to thirteen. You're not paying for a cure. You're paying for access to a captive market. The FDA approves it. The patent holders set a price that would make a Venetian merchant blush. And the system calls it progress. Meanwhile, ask yourself: who sits on the board of Revolution Medicines? Who are the institutional investors? Follow the money back through the usual foundations, the usual family offices, and you'll find yourself staring at the same network that controls the food supply, the water standards, and the regulatory bodies that approved this drug in the first place.

The Controlled Opposition Game

Now look at the trial design. Five hundred patients. Open-label. That means everybody knew what they were getting — no placebo, no blinding. In a trial that small, with that much visibility, you can shape the data. And they did. A hazard ratio of 0.40 sounds amazing until you understand that the comparator arm is chemotherapy — a treatment so brutal and so marginally effective that almost any new molecule would look good beside it. This is not medicine. This is perception shepherding. The American Cancer Society estimates 67,000 new cases this year. The NCI says 90 to 95 percent are this exact adenocarcinoma type. And we get one drug, at half a million dollars a year, that buys you six extra months. They are not trying to cure pancreatic cancer. They are trying to manage it as a chronic revenue stream.

What They're Not Telling You About RAS

Here is where the story gets dark. Rasonque targets the RAS protein family — the same proteins that drive tumor growth in most pancreatic cancers. But RAS is not just a cancer driver. RAS signaling is involved in everything from cell growth to neural development to metabolic regulation. The question nobody in the mainstream press is asking is this: why has it taken so long to develop a RAS inhibitor? The biology has been understood for decades. The answer is not scientific. It's structural. The same institutions that control the research funding, the patent systems, and the regulatory pathways have no incentive to cure a disease they can monetize across a lifetime of marginal treatments. They have been sitting on this knowledge while millions died. They called it "undruggable" until the economics shifted. Now suddenly it's approved. The timing isn't medical. It's financial. And the real research — the things they know about RAS that could actually prevent these cancers — those papers have a way of disappearing or never getting funded. You want to know why pancreatic cancer is still a death sentence? Stop looking at the tumor. Start looking at the system that profits from it.